Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris GlobeNewswire - Thu Dec 18, 2025

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved ...

GUD.TO : 5.91 (+1.90%)
Stocks in play: Knight Therapeutics Inc. Baystreet - Thu Nov 6, 2025

Today reported financial results for its third quarter ended September 30, 2025. Revenues were $121,548, ...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Reports Third Quarter 2025 Results GlobeNewswire - Thu Nov 6, 2025

Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE...

GUD.TO : 5.91 (+1.90%)
Knight Announces Closing of US$100 Million Revolving Credit Facility GlobeNewswire - Fri Oct 31, 2025

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada GlobeNewswire - Thu Oct 30, 2025

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate...

COLL : 47.11 (+2.59%)
GUD.TO : 5.91 (+1.90%)
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call GlobeNewswire - Thu Oct 30, 2025

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina GlobeNewswire - Thu Oct 30, 2025

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada GlobeNewswire - Tue Oct 7, 2025

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX ®...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada GlobeNewswire - Tue Oct 7, 2025

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE...

GUD.TO : 5.91 (+1.90%)
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies GlobeNewswire - Fri Sep 26, 2025

MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine’s...

GUD.TO : 5.91 (+1.90%)

Barchart Exclusives

Analysts Think This Dividend Stock Is Headed for Big Payout Growth Ahead Barchart - Mon Feb 2, 6:30PM CST
Wells Fargo upgraded ConocoPhillips, citing expectations for dividend growth through 2029. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot